Table 1 Clinicopathological characteristics of the discovery set.
NM | LM | M | Total | p | |
|---|---|---|---|---|---|
Age (mean ± SD) | 46 ± 6 | 46 ± 14 | 47 ± 12 | 46 ± 11 | 0.776 |
MFS (mean ± SD) | NA | 8.4 ± 3.1 | 1.6 ± 0.6 | 4.8 ± 4.1 | < 0.001 |
Nuclear grade | 0.115 | ||||
1 | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 1 (3.4%) | |
2 | 5 (50.0%) | 4 (44.4%) | 1 (10.0%) | 10 (34.5%) | |
3 | 5 (50.0%) | 4 (44.4%) | 9 (90.0%) | 18 (62.1%) | |
Histologic grade | 0.070 | ||||
II | 5 (50.0%) | 5 (55.6%) | 1 (10.0%) | 11 (37.9%) | |
III | 5 (50.0%) | 4 (44.4%) | 9 (90.0%) | 18 (62.1%) | |
ER IHC | 0.377 | ||||
Negative | 4 (40.0%) | 3 (33.3%) | 6 (60.0%) | 13 (44.8%) | |
Positive | 6 (60.0%) | 6 (66.7%) | 4 (40.0%) | 16 (55.2%) | |
PR IHC | 0.185 | ||||
Negative | 4 (40.0%) | 5 (55.6%) | 7 (70.0%) | 16 (55.2%) | |
Positive | 6 (60.0%) | 4 (44.4%) | 3 (30.0%) | 13 (44.8%) | |
HER2 status | 1.000 | ||||
Negative | 8 (80.0%) | 8 (88.9%) | 8 (80.0%) | 24 (82.8%) | |
Positive | 2 (20.0%) | 1 (11.1%) | 2 (20.0%) | 5 (17.2%) | |
Subtype | 0.137 | ||||
ER+/HER2− | 6 (60.0%) | 6 (66.7%) | 3 (30.0%) | 15 (51.7%) | |
ER−/HER2+ | 2 (10.0%) | 1 (11.1%) | 2 (20.0%) | 4 (13.8%) | |
TNBC | 2 (20.0%) | 2 (22.2%) | 5 (50.0%) | 10 (34.5%) | |
pT stage | 1.000 | ||||
pT1 | 1 (10.0%) | 2 (22.2%) | 1 (10.0%) | 4 (13.8%) | |
pT2 | 9 (90.0%) | 7 (77.8%) | 9 (90.0%) | 25 (86.2%) | |
pN stage | 1.000 | ||||
pN0 | 10 (100.0%) | 8 (88.9%) | 10 (100.0%) | 28 (96.6%) | |
pN1 | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 1 (3.4%) | |
Stage | 1.000 | ||||
I | 1 (10.0%) | 2 (22.2%) | 1 (10.0%) | 4 (13.8%) | |
II | 9 (90.0%) | 7 (77.8%) | 9 (90.0%) | 25 (86.2%) | |
Total | 10 (34.5%) | 9 (31.0%) | 10 (34.5%) | 29 (100.0%) | |
